Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
about
Targeted therapies and immunotherapy in non-small-cell lung cancerThe role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancerNon-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategyIntrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsSpotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so farThe steady progress of targeted therapies, promising advances for lung cancerRecent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCTyrosine Kinase Inhibitors for the ElderlyAfatinib in Non-Small Cell Lung CancerImmunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent CancersProgrammed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta roleCirculating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerDacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?Targeting RTK Signaling Pathways in CancerMore than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future HoldsIdentifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancerA decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesRisk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsUpdate in Lung Cancer 2014CIViC databaseIn vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancerSpotlight on pembrolizumab in non-small cell lung cancer: the evidence to dateTherapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidenceUnravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsPersonalized treatment of advanced non-small-cell lung cancer in routine clinical practiceMechanisms of resistance to EGFR-targeted drugs: lung cancerNext-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceAntacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsHydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib.Lung cancer in Brazil: epidemiology and treatment challenges.Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment?Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.UGT genotyping in belinostat dosingPemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG).A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature.
P2860
Q26738986-EE793E22-C79B-43AA-87C0-49BB991D1BEDQ26740529-0576018A-4E00-4541-A709-CDF1935EC965Q26741814-CA26CFB0-B52C-4DA3-B769-A7FD8487B1A3Q26744284-B758654C-5190-4FAB-BD90-A1F5771CF0B1Q26744339-FE510AC3-BD06-4327-8316-39F442234515Q26745776-8C021B7D-168F-4FA2-AC9E-8A47DE7B99AAQ26746895-D60EAA45-C940-41A9-A898-F4DD637260D8Q26747276-2B73D49E-87F9-49A9-BC56-6343C5B12409Q26748567-2D17F48B-4EAF-408C-B034-C768174DCD1DQ26749005-6F17F4C0-AA28-4E4F-80B2-58727BA333D7Q26751473-1A97D05E-4477-4C0C-A1D4-CADFDC0B40A0Q26769734-8C8B4522-D8D7-4AAD-AB9F-BBB03E825E3DQ26775376-0FA25611-F9A2-4016-9D98-3F393BA86E14Q26778318-65ECDA7D-AF12-49FA-BE17-F29A047DA3DFQ26781278-86B23F82-555D-47A9-B1E0-D5E1A007BD0AQ26781662-89C0E472-06A6-4613-AAD1-87FFE90B3FD0Q26781810-3BB352C4-FCC6-448B-BC44-015575324831Q26797297-D52874E0-116D-4E79-83F5-49FC3C61D1DBQ26851417-59EA1529-0884-42D5-AFC7-A97EF387CCCAQ27027385-3A384047-81E6-4FF7-95B3-85E1180DE277Q27612411-1607078D-2DE3-4A7F-859B-522E4DA8303EQ27853236-E79948D9-1678-403B-97BB-213251DBFDCCQ28067610-94DDCA7B-5C03-4898-95E4-F64D34254E89Q28071772-6E08085D-3804-4217-9952-1E150106E1AAQ28075291-698B92F6-43D7-4E3F-A73C-803662A8ABADQ28075800-BC7DD27E-59E6-4D2B-8D60-3E8E0A42F3C2Q28077415-8F12583A-B6FB-4CA7-84F7-043B6C26D656Q28079320-7B8ADFFE-6388-42F0-B100-9CE4F8C6471EQ28550276-7F49E5C9-31C8-4466-AE6E-59E782996BCAQ29994744-77463A86-F2B5-4BA6-BA4D-5E741EF5965AQ30235908-E32D6EA8-9273-41C1-95A5-DEC51B1CF0F7Q30316339-4E4BB77B-F7F6-4FEC-A9E1-996DB06A45E4Q31160116-A395494E-7E51-4332-9F25-659533456663Q33423782-199038CB-71E2-45AE-B974-A2F9FB907B53Q33429235-ACD6286F-FE8D-4267-9933-77BFABDD0085Q33432327-122AAD3F-DA7F-44E6-B1C6-54B2BEFC5720Q33433360-07C20D2F-C8A1-44FC-8EE3-D60C019A5D10Q33435236-98C69533-572B-41DF-8682-73B64AC52B68Q33633715-576ED001-6316-4304-A089-CB6D57BD9E39Q33653615-49517325-5D79-41D7-A03F-F20197C3576F
P2860
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Afatinib versus cisplatin-base ...... wo randomised, phase 3 trials.
@ast
Afatinib versus cisplatin-base ...... wo randomised, phase 3 trials.
@en
Afatinib versus cisplatin-base ...... wo randomised, phase 3 trials.
@nl
type
label
Afatinib versus cisplatin-base ...... wo randomised, phase 3 trials.
@ast
Afatinib versus cisplatin-base ...... wo randomised, phase 3 trials.
@en
Afatinib versus cisplatin-base ...... wo randomised, phase 3 trials.
@nl
prefLabel
Afatinib versus cisplatin-base ...... wo randomised, phase 3 trials.
@ast
Afatinib versus cisplatin-base ...... wo randomised, phase 3 trials.
@en
Afatinib versus cisplatin-base ...... wo randomised, phase 3 trials.
@nl
P2093
P50
P921
P3181
P1433
P1476
Afatinib versus cisplatin-base ...... wo randomised, phase 3 trials.
@en
P2093
Caicun Zhou
Cheng-Ping Hu
Chun-Ming Tsai
Dan Massey
Jaafar Bennouna
Jifeng Feng
Kenneth O'Byrne
Ki Hyeong Lee
Kye Young Lee
Lecia V Sequist
P304
P3181
P356
10.1016/S1470-2045(14)71173-8
P577
2015-02-01T00:00:00Z